The news that Roche ($RHHBY) struck a deal to buy InterMune ($ITMN) for $8.3 billion reportedly came at the expense of Chugai's investors. Roche had earlier been kicking around a deal to buy out the remaining stake in Chugai it doesn't already own for about $10 billion. But the InterMune deal took precedence and now Roche will leave Chugai alone, reports Bloomberg. Chugai, for its part, said there never was a deal on the table. And Roche CEO Severin Schwan had earlier ruled out an offer. Chugai's shares took a hit as investors finally got the message: No deal. Report